Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S25-S31

  Gumbo, Tawanda ^a,b   Pasipanodya, Jotam G ^a   Romero, Klaus ^c   Hanna, Debra ^c   Nuermberger, Eric ^d  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c CRITICAL PATH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug development tool; Hollow fiber system; Monte Carlo experiments; Predictive accuracy; Tuberculosis

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL STUDY; DRUG DEVELOPMENT; DRUG EXPOSURE; FORECASTING; HINDSIGHT BIAS; HOLLOW FIBER MODEL OF TUBERCULOSIS; HUMAN; MATHEMATICAL MODEL; MEASUREMENT ERROR; MONTE CARLO METHOD; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUBERCULOSIS; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; STANDARDS; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84942084425     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ427     Document Type: Article

References (50)

1. Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2014; 2:321-38.
2. Gumbo T, Lenaerts AJ, Hanna D, Romero K, Nuermberger E. Nonclinical models for antituberculosis drug development: a landscape analysis. J Infect Dis 2015; 211(suppl 3):S83-95.
3. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 2015; 211(suppl 3):S96-106.
4. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb) 2008; 88(suppl 1):S65-74.
5. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190:1642-51.
6. Drusano GL. US Food and Drug Administration. In: Meeting of the Food and Drug Administration Advisory Committee for the Division of Anti-Infective Drug Products. 1998.
7. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45:13-22.
8. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55:24-34.
9. Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 2015; 61(suppl 1):S10-7.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
11. The Periodic Health Examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979; 121:1193-254.
12. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51:2329-36.
13. Gumbo T, Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53:3197-204.
14. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. MBio 2010; 1:e00139-10.
15. Gumbo T, Louie A, Deziel MR, Drusano GL. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005; 49:3178-81.
16. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51:3781-8.
17. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194-201.
18. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54:1484-91.
19. Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother 2011; 55:539-45.
20. Srivastava S, Sherman C, Meek C, Leff R, Gumbo T. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother 2011; 55:5085-9.
21. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010; 201:1225-31.
22. Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. MBio 2011; 2:e00108-11.
23. Louie A, Brown D, Swift M, Files K, Fikes S, Drusano GL. Clinical doses of PNU-100480 (U, sutezolid) plus rifampin (R) synergistically kills Mycobacterium tuberculosis (Mtb) while linezolid (L) plus R does not. In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012.
24. Okusanya OO, Forrest A, Bulik CC, et al. Analyses for rifampin (RIF) in combination with sutezolid (SUT) or linezolid (LZD) against Mycobacterium tuberculosis (Mtb) in log-phase (LP) using data from a hollow fiber infection model. In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012.
25. Okusanya OO, Forrest A, Bulik CC. PK/PD analyses of the effects of sutezolid (SUT), linezolid (LZD), and rifampin (RIF), alone and in combination, against Mycobacterium tuberculosis (Mtb) in acid-phase (AP) growth using data from a hollow fiber infection model (HFIM). In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012.
26. Goutelle S, Bourguignon L, Maire PH, Van GM, Conte JE Jr, Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009; 53:2974-81.
27. Goutelle S, Bourguignon L, Jelliffe RW, Conte JE Jr, Maire P. Mathematical modeling of pulmonary tuberculosis therapy: insights from a prototype model with rifampin. J Theor Biol 2011; 282:80-92.
28. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9.
29. Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A. Exposure-response of Mycobacterium tuberculosis (Mtb) in the state of Wayne-Hayes level II anaerobiosis to moxifloxacin (M). In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012.
30. Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A. Prediction of clinical outcome from hollow fiber infection model (HFIM) data for rifampin (RIF) therapy of M. tuberculosis (Mtb) in nonreplicative persister (NRP) phase. In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9-12 September 2012.
31. Ginsburg AS, Lee J, Woolwine SC, Grosset JH, Hamzeh FM, Bishai WR. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother 2005; 49:853-6.
32. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009; 180:365-70.
33. Chang KC, Leung CC, Yew WW, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Eur Respir J 2010; 35:606-13.
34. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
35. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis 2007; 45:1409-14.
36. Chatterjee A, Saranath D, Bhatter P, Mistry N. Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance. PLoS One 2013; 8: e54717.
37. Machado D, Couto I, Perdigao J, et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 2012; 7:e34538.
38. Louw GE, Warren RM, Gey van Pittius NC, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011; 184:269-76.
39. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169-77.
40. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464-73.
41. Chigutsa E, Pasipanodya JG, Visser ME, et al. The impact of non-linear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 2015; 59:38-45.
42. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:852-7.
43. Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother 2014; 58:6111-5.
44. Gumbo T, Chigutsa E, Pasipanodya J, et al. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother 2014; 69:2420-5.
45. Pranger AD, van AR, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38:888-94.
46. Pranger AD, Kosterink JG, van AR, et al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 2011; 33:350-4.
47. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011; 55: 3244-53.
48. Williamson DA, Roberts SA, Bower JE, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012; 16:216-20.
49. Schmalstieg AM, Srivastava S, Belkaya S, et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 2012; 56:4806-15.
50. Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis 2013; 57:21-31.